IRLAB Therapeutics AB (publ) (STO:IRLAB.A)

Sweden · Delayed Price · Currency is SEK

2.000

+0.018 (0.91%)

At close: Jan 15, 2026

Revenue by Product

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	2014 - 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '19 Dec 31, 2019	2014 - 2018
Mesdopetam, Pirepemate and Integrative Screening Process	94.63M	Log In	Log In	Log In	Log In	Upgrade
Mesdopetam, Pirepemate and Integrative Screening Process Growth	1566.57%	Log In	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	2014 - 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '19 Dec 31, 2019	2014 - 2018
United States	94.63M	Log In	Log In	Log In	Log In	Upgrade
United States Growth	2142.37%	Log In	Log In	Log In	Log In	Upgrade
United Kingdom	-	Log In	Log In	Log In	Log In	Upgrade
United Kingdom Growth	-	Log In	Log In	Log In	Log In	Upgrade
Sweden	-	Log In	Log In	Log In	Log In	Upgrade
Sweden Growth	-	Log In	Log In	Log In	Log In	Upgrade